Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Patients with Parkinson's Disease

• Patients with L-dopa induced dyskinesia for at least 3 months

• Patients with L-dopa treatment for at least 3 years, stable for 1 month minimum

Exclusion Criteria:

• History of severe allergy to food or drugs

• Very low or high body weight.

• Prior surgery for Parkinson's Disease

• Smokers

Other protocol-defined inclusion/exclusion criteria may apply